Inicio>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>NH-bis-PEG2

NH-bis-PEG2

Catalog No.GC67456

NH-bis-PEG2 es un conector ADC de PEG de 2 unidades no escindible que se utiliza en la síntesis de conjugados de anticuerpo-fármaco (ADC). NH-bis-PEG2 también es un enlazador PROTAC basado en PEG que se puede utilizar en la síntesis de PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

NH-bis-PEG2 Chemical Structure

Cas No.: 54384-47-3

Tamaño Precio Disponibilidad Cantidad
250mg
978,00 $
Disponible
500mg
1.558,00 $
Disponible
1g
2.408,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

NH-bis-PEG2 is a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). NH-bis-PEG2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

[1]. Brown A, et al. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder. Sci Rep. 2016 Aug 30;6:31750.

Reseñas

Review for NH-bis-PEG2

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NH-bis-PEG2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.